Advertisement
Home »

Patients With HCC Often Prioritize QOL Over Survival

Jul 24, 2023

REFERENCES & ADDITIONAL READING

Patient Preferences for Unresectable Hepatocellular Carcinoma Treatments: A Discrete-Choice Experiment
https://www.mdpi.com/2072-6694/15/5/1470

ABOUT THE EXPERTS

  • Daneng Li, MD

    Daneng Li, MD
    Associate Professor
    Department of Medical Oncology & Therapeutics Research
    City of Hope Comprehensive Cancer Center

    Daneng Li, MD, has indicated to Physician’s Weekly that he has received advisory/consultancy fees and honoraria from Adagene, Eisai, Exelixis, Genentech, Ipsen, Merck, and Mina Therapeutics, and institutional research funding from AstraZeneca and Brooklyn Immunotherapeutics.

MORE ARTICLES BELOW

PW Weekly Newsletters

The latest articles and insights from your colleagues in your specialty(ies) of choice.


EXPLORE MORE

Advertisement
Advertisement
ad
ad
MORE ARTICLES BELOW

PW Weekly Newsletters

The latest articles and insights from your colleagues in your specialty(ies) of choice.

SUBSCRIBE NOW

View all newsletters

RELEVANT ARTICLES FOR YOU

Advertisement